Multiple sclerosis patients less likely to have molecular hallmarks of Alzheimer’s disease

People with multiple sclerosis (MS) are far less likely than those without the condition to have the molecular hallmarks of Alzheimer’s disease, according to new research from Washington University School of Medicine in St. Louis.

AmplifyBio and Xcell enter TCR-T cell therapy manufacturing deal

A cGMP cell therapy manufacturing system, AVATAR Foundry is designed to enhance the potency of cell and gene therapies. Credit: Gorodenkoff / Shutterstock.com. AmplifyBio and

May 21, 2024

Researchers identify genes linked to muscle aging and sarcopenia

Scientists have identified previously unreported genes which appear to play a key role in the muscle ageing process.

October 26, 2024

FDA approved PDE4 inhibitor roflumilast for atopic dermatitis

On July 9th, 2024, the U.S. FDA approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) for treating atopic dermatitis (AD), the most common type of eczema affecting millions

July 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.